GSK announced the discontinuation of Phase 3 development for Camlipixant in refractory chronic cough (RCC). This is a negative clinical/progress update that may raise uncertainty around the program’s future value and pipeline outlook.
GSK announced the discontinuation of Phase 3 development for Camlipixant in refractory chronic cough (RCC). This is a negative clinical/progress update that may raise uncertainty around the program’s future value and pipeline outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
